Top

Published in:

01-08-2013 | Clinical Study

Adult primitive neuroectodermal tumors: the prognostic value of supratentorial location

Authors: Rikesh Gandhi, Ranjith Babu, Thomas J. Cummings, Cory Adamson

Published in: Journal of Neuro-Oncology | Issue 1/2013

Abstract

Primitive neuroectodermal tumors (PNETs) are tumors which primarily consist of undifferentiated round neuroepithelial cells. Central nervous system PNETs can be divided into two genetically distinct groups: infratentorial PNET (iPNET)/medulloblastoma and supratentorial PNET (sPNET). Currently, the comparative outcome of adult patients with sPNETs and iPNETs is unknown. In this study we have utilized the Surveillance, Epidemiology, and End Results database to perform a comparative analysis of 103 cases of adult sPNET and 669 adult medulloblastoma cases. Additionally we have analyzed various factors to identify their prognostic significance and characterize the optimal treatment for these tumors. Patients with sPNETs were seen to have a significantly worse survival than those diagnosed with medulloblastomas (16 vs. 155 months, p < 0.0001). Elderly patients (15 vs. 114 months, p < 0.0001) and those over the age of 40 (68 vs. 147 months, p < 0.0001) experienced significantly worse survival than younger patients. In contrast, radiotherapy (143 vs. 26 months, p < 0.0001), surgical resection (116 vs. 22 months, p = 0.0010) and the extent of resection (EOR) (173 vs. 81 months, p = 0.0005) resulted in significantly improved patient survival. Multivariate analysis revealed age greater than 40 years (HR: 1.57; 95 % CI: 1.17–2.11; p = 0.0028) and sPNET pathology (HR: 3.41; 95 % CI: 2.47–4.72; p < 0.0001) to be poor prognostic factors for survival while radiotherapy (HR: 0.52; 95 % CI: 0.38–0.71; p < 0.0001) and the EOR (HR: 0.73; 95 % CI: 0.55–0.96; p = 0.023) were associated with significantly improved survival. The treatment of sPNETs should therefore include maximal surgical resection when feasible followed by radiotherapy as these treatments have been demonstrated to confer a survival benefit. Additional studies are needed to identify effective chemotherapeutics and specific treatment regimens for adults with sPNETs.

Hart MN, Earle KM (1973) Primitive neuroectodermal tumors of the brain in children. Cancer 32(4):890–897PubMedCrossRef

Balafouta MJ, Kouvaris JR, Miliadou AC et al (2003) Primitive neuroectodermal tumour in a 60-year-old man: a case report and literature review. Br J Radiol 76(901):62–65PubMedCrossRef

Baldini EH, Demetri GD, Fletcher CD et al (1999) Adults with Ewing’s sarcoma/primitive neuroectodermal tumor. Ann Surg 230(1):79–86PubMedCrossRef

Majos C, Juli A, Aguilera C et al (2002) Adult primitive neuroectodermal tumor: proton MR spectroscopic findings with possible application for differential diagnosis. Radiology 225(2):556–566PubMedCrossRef

Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. doi:10.1007/s00401-007-0243-4 PubMedCrossRef

Krampulz T, Hans VH, Oppel F et al (2006) Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report. J Neurooncol 77(3):291–294. doi:10.1007/s11060-005-9041-9 PubMedCrossRef

Burnett ME, White EC, Sih S et al (1997) Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system. Cancer Genet Cytogenet 97(1):25–31PubMedCrossRef

Russo C, Pellarin M, Tingby O et al (1999) Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86(2):331–339PubMedCrossRef

Inda MM, Perot C, Guillard-Bataille M et al (2005) Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology 47(6):631–637. doi:10.1111/j.1365-2559.2005.02304.x PubMedCrossRef

10.

Schutz BR, Scheurlen W, Krauss J et al (1996) Mapping of chromosomal gains and losses in primitive neuroectodermal tumors by comparative genomic hybridization. Genes Chromosom Cancer 16(3):196–203. doi:10.1002/(SICI)1098-2264(199607)16:3<196:AID-GCC7>3.0.CO;2-U PubMedCrossRef

11.

Biswas S, Burke A, Cherian S et al (2009) Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation? Pediatr Blood Cancer 52(7):796–803. doi:10.1002/pbc.21899 PubMedCrossRef

12.

Masuda K, Yutani C, Akutagawa K et al (2004) Cerebral primitive neuroectodermal tumor in as adult male: a case report. Acta Cytol 44(6):1050–1058CrossRef

13.

Ohba S, Kazunari Y, Hirose Y et al (2008) A supratentorial primitive neuroectodermal tumor in an adult: a case report and review of literature. J Neurooncol 86(2):217–224. doi:10.1007/s11060-007-9466-4 PubMedCrossRef

14.

Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA (2002) Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 94(11):835–844PubMedCrossRef

15.

Reardon DA, Michalkiewicz E, Boyett JM et al (1997) Extensive genomic abnormalities in childhood medulloblastomas by comparative genomic hybridization. Cancer Res 57(18):4042–4047PubMed

16.

Cogen PH, McDonald JD (1996) Tumor suppressor genes and medulloblastoma. J Neurooncol 29(1):103–112PubMedCrossRef

17.

Kraus JA, Felsberg J, Tonn JC, Reifenberger G, Pietsch T (2002) Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol 28(4):325–333PubMedCrossRef

18.

Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C (2010) Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28(8):1345–1350. doi:10.1200/JCO.2009.23.5952 PubMedCrossRef

19.

Raffel C, Thomas GA, Tishler DM, Lassoff S, Allen JC (1993) Absence of p53 mutations in childhood central nervous system primitive neuroectodermal tumors. Neurosurgery 33(2):301–305PubMedCrossRef

20.

Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57(19):4187–4190PubMed

21.

Kim DG, Lee DY, Paek SH et al (2002) Supratentorial primitive neuroectodermal tumors in adults. J Neurooncol 60(1):43–52PubMedCrossRef

22.

Dirks PB, Harris L, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT (1996) Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 29(1):75–84PubMedCrossRef

23.

Lai R (2008) Survival of patients with adult medulloblastoma: a population-based study. Cancer 112(7):1568–1574. doi:10.1002/cncr.23329 PubMedCrossRef

24.

van den Bent MJ, Stupp R, Brandes AA, Lacombe D (2004) Current and future trials of the EORTC brain tumor group. Onkologie 27(8):246–250. doi:10.1200/JCO.2008.17.5984 PubMedCrossRef

25.

Kouyialis AT, Boviatsis EI, Karampelas IK et al (2005) Primitive supratentorial neuroectodermal tumor in an adult. J Clin Neurosci 12(4):492–495. doi:10.1016/j.jocn.2004.07.014 PubMedCrossRef

26.

Pickuth D, Leutloff U (1996) Computed tomography and magnetic resonance image findings in primitive neuroectodermal tumours in adults. Br J Radiol 69(817):1–5PubMedCrossRef

27.

Asmoniene V, Skiriute D, Gudinaviciene I et al (2011) A primary primitive neuroectodermal tumor of the central nervous system in a 51-year-old woman: a case report and literature review. Medicina 47(8):440–445PubMed

28.

Bellis EH, Salcman M, Bastian FO et al (1983) Primitive neuroectodermal tumor in a 57-year-old man. Surg Neurol 20(1):30–35PubMedCrossRef

29.

Miyazawa T, Ueno H, Hatashita S et al (1994) “Undifferentiated” cerebral primitive neuroectodermal tumor in a young adult. Neurol Med Chir 34(11):759–762CrossRef

30.

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115(1):3–8. doi:10.3171/2011.2.JNS10998 PubMedCrossRef

31.

Gaffney CC, Sloane JP, Bradley NJ, Bloom HJ (1985) Primitive neuroectodermal tumours of the cerebrum. Pathology and treatment. J Neurooncol 3(1):23–33PubMedCrossRef

32.

Malheiros SM, Franco CM, Stavale JN et al (2002) Medulloblastoma in adults: a series from Brazil. J Neurooncol 60(3):247–253PubMedCrossRef

33.

Momota H, Shih AH, Edgar MA et al (2008) c-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene 27(32):4392–4401. doi:10.1038/onc.2008.81 PubMedCrossRef

34.

Gessi M, Setty P, Bisceglia M et al (2011) Supratentorial primitive neuroectodermal tumors of the central nervous system in adults: molecular and histopathologic analysis of 12 cases. Am J Surg Pathol 35(4):573–582. doi:10.1097/PAS.0b013e31820f1ce0 PubMedCrossRef

35.

Hayden JT, Fruhwald MC, Hasselblatt M et al (2009) Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 8(11):1806–1807PubMedCrossRef

36.

Louis DN, Hochberg FH (1990) Cerebral primitive neuroectodermal tumor in an adult, with spinal cord metastasis after 18-year dormancy. J Neurooncol 9(1):77–80PubMedCrossRef

37.

McBride SM, Daganzo SM, Banerjee A et al (2008) Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys 72(5):1319–1323. doi:10.1016/j.ijrobp.2008.03.033 PubMedCrossRef

Title: Adult primitive neuroectodermal tumors: the prognostic value of supratentorial location
Authors: Rikesh Gandhi
Ranjith Babu
Thomas J. Cummings
Cory Adamson
Publication date: 01-08-2013
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1163-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adult primitive neuroectodermal tumors: the prognostic value of supratentorial location

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from neuritin

Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer

MR perfusion in and around the contrast-enhancement of primary CNS lymphomas

Increased glutamate uptake in astrocytes via propentofylline results in increased tumor cell apoptosis using the CNS-1 glioma model

Caloric restriction reduces edema and prolongs survival in a mouse glioma model

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience